Classifications

• • D—TEXTILES; PAPER
  • D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
  • D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
  • D01F1/00—General methods for the manufacture of artificial filaments or the like
  • D01F1/02—Addition of substances to the spinning solution or to the melt
  • D01F1/10—Other agents for modifying properties
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
  • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
  • A61K33/24—Heavy metals; Compounds thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
  • A61K33/24—Heavy metals; Compounds thereof
  • A61K33/242—Gold; Compounds thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
  • A61K33/24—Heavy metals; Compounds thereof
  • A61K33/243—Platinum; Compounds thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
  • C08K3/00—Use of inorganic substances as compounding ingredients
  • C08K3/02—Elements
  • C08K3/08—Metals
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
  • C08K3/00—Use of inorganic substances as compounding ingredients
  • C08K3/18—Oxygen-containing compounds, e.g. metal carbonyls
  • C08K3/20—Oxides; Hydroxides
  • C08K3/22—Oxides; Hydroxides of metals
• • C—CHEMISTRY; METALLURGY
  • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
  • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
  • C09K3/00—Materials not provided for elsewhere
• • C—CHEMISTRY; METALLURGY
  • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
  • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
  • C04B2235/00—Aspects relating to ceramic starting mixtures or sintered ceramic products
  • C04B2235/02—Composition of constituents of the starting material or of secondary phases of the final product
  • C04B2235/30—Constituents and secondary phases not being of a fibrous nature
  • C04B2235/32—Metal oxides, mixed metal oxides, or oxide-forming salts thereof, e.g. carbonates, nitrates, (oxy)hydroxides, chlorides
  • C04B2235/3217—Aluminum oxide or oxide forming salts thereof, e.g. bauxite, alpha-alumina
• • C—CHEMISTRY; METALLURGY
  • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
  • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
  • C04B2235/00—Aspects relating to ceramic starting mixtures or sintered ceramic products
  • C04B2235/02—Composition of constituents of the starting material or of secondary phases of the final product
  • C04B2235/30—Constituents and secondary phases not being of a fibrous nature
  • C04B2235/32—Metal oxides, mixed metal oxides, or oxide-forming salts thereof, e.g. carbonates, nitrates, (oxy)hydroxides, chlorides
  • C04B2235/3231—Refractory metal oxides, their mixed metal oxides, or oxide-forming salts thereof
  • C04B2235/3232—Titanium oxides or titanates, e.g. rutile or anatase
• • C—CHEMISTRY; METALLURGY
  • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
  • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
  • C04B2235/00—Aspects relating to ceramic starting mixtures or sintered ceramic products
  • C04B2235/02—Composition of constituents of the starting material or of secondary phases of the final product
  • C04B2235/30—Constituents and secondary phases not being of a fibrous nature
  • C04B2235/34—Non-metal oxides, non-metal mixed oxides, or salts thereof that form the non-metal oxides upon heating, e.g. carbonates, nitrates, (oxy)hydroxides, chlorides
  • C04B2235/3418—Silicon oxide, silicic acids, or oxide forming salts thereof, e.g. silica sol, fused silica, silica fume, cristobalite, quartz or flint
• • C—CHEMISTRY; METALLURGY
  • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
  • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
  • C04B2235/00—Aspects relating to ceramic starting mixtures or sintered ceramic products
  • C04B2235/02—Composition of constituents of the starting material or of secondary phases of the final product
  • C04B2235/30—Constituents and secondary phases not being of a fibrous nature
  • C04B2235/40—Metallic constituents or additives not added as binding phase
  • C04B2235/408—Noble metals
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
  • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
  • Y10T428/00—Stock material or miscellaneous articles
  • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
  • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Definitions

• the present invention relates to a platinum-containing ceramic composition having antithrombotic properties. More specifically, the present invention relates to a antithrombotic composition comprising alumina, one or more types of substances selected from silica or titanium oxide, and one or more types of substances selected from platinum, palladium, iridium, rhodium or a compound thereof, as well as antithrombotic articles containing that composition.
• Japanese Provisional Patent Publication No. 184088/1987 describes that a powder for radiating far infrared rays that contains alumina, silica and platina has the effect of aging and improving shelf life and flavor of food products.
• Japanese Provisional Patent Publication No. 190990/1991 describes that a powder for radiating weak infrared energy that contains alumina, titanium and platina has the effect of aging and improving shelf life and flavor of food products, that synthetic fibers containing this powder promote blood circulation, have heating effects and are effective against poor circulation and symptoms of arthritis.
• Japanese Provisional Patent Publication No. 241025/1991 and Japanese Provisional Patent Publication No. 73226/1992 describe that a textile produced from threads obtained by mixing a powder for radiating far infrared rays composed of alumina, silica and platina with Nylon or polyester demonstrates extremely satisfactory warmth retaining properties for the body.
• an object of the present invention is to discover a novel application for a ceramic composition containing platinum.
• the present invention provides an antithrombotic composition
• an antithrombotic composition comprising: (i) alumina, (ii) at least one substance selected from silica and titanium oxide, and (iii) at least one element or compound selected from platinum or a platinum compound, palladium or a palladium compound, iridium or an iridium compound and rhodium or a rhodium compound.
• the present invention also relates to the above antithrombotic composition additionally comprising: (iv) at least one element or compound selected from silver or a silver compound or gold or a gold compound.
• the present invention relates to antithrombotic articles that contain the above antithrombotic composition, and particularly clothing and bedding.
• the alumina (Al 2 O 3 ) of component (i) contained in the composition of the present invention preferably uses high-purity alumina (aluminum oxide) having a purity of 99.9% or higher and superior sintering. Commercially available, powdered high-purity alumina can be used for the alumina.
• the content of component (i) is preferably 20-60 parts by weight, and more preferably 30-50 parts by weight.
• the particle diameter of component (i) depends on the product that uses the composition of the present invention and its mode, the component having a normal particle diameter, for example, several ⁇ m or less can be used.
• the particle diameter of component (i) is preferably adjusted depending on the diameter of the fibers, and is normally 2 ⁇ m or less, preferably 1.5 ⁇ m or less, more preferably 1.0 ⁇ m or less, for example, a particle diameter of about 0.3 ⁇ m.
• the silica (SiO 2 ) of component (ii) contained in the composition of the present invention is preferably high-purity silica having a purity not less than 99.8%, and for example, commercially available microparticulate anhydrous silica may be used.
• the particle diameter of the silica is the same as that of component (i).
• the purity, particle diameter and blended amount of the titanium oxide (TiO 2 ) of component (ii) contained in the composition of the present invention are the same as those of the previously mentioned component (ii).
• Commercially available microparticulate titanium oxide may be used.
• high-purity, hyperfine titanium dioxide, obtained by granulating and purifying from coarse particles of titanium dioxide having a purity of 80% or higher, may also be used.
• Component (ii) consisting of one or more types of compounds selected from silica and titanium oxide is contained in the composition of the present invention at preferably 40-80 parts by weight, and more preferably 50-70 parts by weight.
• Titanium oxide is preferably used for component (ii) in the antithrombotic composition of the present invention.
• At least one type of element or compound thereof selected from platinum or a platinum compound, palladium or a palladium compound, iridium or an iridium compound and rhodium or a rhodium compound of component (iii) contained in the composition of the present invention is preferably added in the form of a colloid. This is because so-called colloidal activation can be expected that results in the adsorption of oxygen and hydrogen. Platinum or a platinum compound is preferably used for component (iii).
• Component (iii) is contained as metal in the composition of the present invention preferably at 0.0005-0.010 parts by weight, and more preferably at 0.001-0.004 parts by weight.
• a dispersed colloid of component (iii) (to be referred to as a component (iii) colloid), in which component (iii) is dispersed in the form of a colloid in, for example, a hydrochloric acid solution at a particle diameter of about 0.7-4 nm (7-40 ⁇ ), is preferably used for component (iii).
• Component (iii) is used by being contained in a colloid at 0.1-5% by weight, preferably 0.5-2% by weight and more preferably 0.8-1.2% by weight, and in consideration of the concentration of component (iii) in the colloid, component (iii) is added so as to be contained at 0.0005-0.010 parts by weight in the composition.
• ordinary methods can be used for preparing the component (iii) colloid. For example, a commercially available platinum colloidal solution containing 1% by weight of platinum may be used.
• the silver or silver compound or gold or gold compound of component (iv) arbitrarily used in the composition of the present invention is preferably used in the form of a powder, and a commercially available silver powder may be used.
• Component (iv) is contained as silver in the composition of the present invention at 0-10 parts by weight, preferably 0.5-5 parts by weight, and more preferably 0.7-2.0 parts by weight.
• composition of the present invention may also contain silicon nitride.
• Silicon nitride enhances the action of hydrogen, and is thought to fulfill the role of restricting the direction of movement of hydrogen ions to a specific direction.
• silicon nitride is contained, it is preferably contained in an amount of 3 parts by weight or less.
• the antithrombotic composition of the present invention can be produced by mixing one or more types of substances selected from alumina, silica and titanium oxide with platinum or platinum oxide respectively dispersed in a colloid, loading the platinum on each of the particles, mixing the particles loaded with platinum by stirring, and as necessary, also mixing in a powder of silver, gold or compound thereof.
• the antithrombotic composition of the present invention can also be produced by adding a predetermined amount of platinum colloid into a predetermined amount of alumina particles only, adding silica and/or titanium oxide to the alumina loaded with platinum, mixing by stirring, adding silver powder and again mixing by stirring.
• the composition of the present invention can be produced by mixing platinum colloid with a powder raw material composed of one or more types of the previously mentioned component (i), component (ii) and component (iv) which is an arbitrary component, diluting with a solvent and so forth until it has a desired sprayable fluidity, and heating for about 10 minutes to 1 hour at about 50-150° C. after spraying.
• a solvent can be used for the diluting solvent provided it does not inhibit the effects of the composition of the present invention, examples of which include pure water and alcohol.
• a known dispersant may be added to improve dispersivity.
• the antithrombotic composition of the present invention can be produced in the form of a fine particulate powder having a particle diameter of 0.1-2.0 ⁇ m, and preferably 0.2-1.0 ⁇ m.
• the present invention also relates to an antithrombotic article containing the antithrombotic composition described above.
• articles include clothing such as undergarments (such as underpants, tights, stockings and hosiery), sleepwear (such as pajamas, sleeping robes and negligees), Western style clothing (such as sweaters, shirts, trousers, skirts and blouses), Oriental clothing (such as kimonos, vests and long shirts) and aprons, bedding such as futons, futon covers, blankets, sheets, mattress pads, pillows, pillow covers and mattresses, accessories such as socks, hats, neckties, handkerchiefs and waist bands, footwear such as shoes, floor coverings such as carpeting, curtains, and furniture such as beds and chairs, with clothing and bedding being particularly preferable examples.
• clothing such as undergarments (such as underpants, tights, stockings and hosiery), sleepwear (such as pajamas, sleeping robes and negligees), Western style clothing (such as sweaters, shirts,
• An antithrombotic article of the present invention can be produced by, for example, blending the antithrombotic composition into the article material or adhering to the surface of the article.
• a method in which 0.1-25% by weight, preferably 0.1-3% by weight, and more preferably 0.3-1.5% by weight of the antithrombotic composition is mixed into a synthetic polymer material of the fiber material; this mixture is then spun into filaments or hollow fibers and so forth using a commonly employed spinning method such as the melting method to obtain a thread; textiles and knits are produced from the resulting threads; and these can then be used to produce bedding and sleepwear such as futons, sheets, blankets, mattress pads, pillows, pillow covers, shirts, trousers and pajamas using conventional methods.
• Various types of textiles, bedding and sleepwear can also be obtained by blending threads containing the composition of the present invention obtained in the manner described above with other threads not containing the composition of the present invention, such as cotton, hemp, silk, wool and other natural fibers or synthetic fibers.
• the antithrombotic composition of the present invention can also be blended into an article material by mixing the antithrombotic composition of the invention into a synthetic resin material and producing molded products of any desired shape such as sphere-like, oval-like, cylinder-like, plate-like, laminate-like or pipe-like, and then, for example, using the resulting pipes as the filling material of a pillow.
• a method in which a mixture consisting of the antithrombotic composition and a synthetic polymer material is sprayed, coated to the article, or the article is dipped into the mixture.
• the synthetic polymer materials include Nylon, Vinylon, esters, acryls, urethanes, polyamides, polyesters, polyacrylonitriles, polyolefins and acetates.
• additives such as magnesium oxide, mica, calcium carbonate and zeolite, plasticizers, UV absorbers, fillers, colorants, coloring preventives, flame retardants, anti-bleeding agents, stabilizers, heat resistance agents and fluorescent whiteners.
• catalysts such as magnesium oxide, mica, calcium carbonate and zeolite, plasticizers, UV absorbers, fillers, colorants, coloring preventives, flame retardants, anti-bleeding agents, stabilizers, heat resistance agents and fluorescent whiteners.
• An article obtained by the above method is able to prevent a decrease in the content of antithrombotic composition since each component of the antithrombotic composition is firmly adhered within the fibers or molded article.
• the content of the composition of the present invention can be increased by such methods as compared with conventional methods.
• Examples of materials that can be used as bedding materials of the present invention include threads (such as filaments and staples), hollow fibers, textiles, knits, non-woven fabrics and any desirable shaped molded products (such as sphere-like, oval-like, cylinder-like, plate-like, laminate-like and pipe-like) containing the antithrombotic composition of the present invention.
• alumina, silica and titanium oxide (titania) were adjusted in particle size to a particle size of 1 ⁇ m or less each.
• 0.083 parts by weight aliquots namely, containing 0.0008 parts by weight of platinum each
• a platinum colloid solution containing 1% platinum (Tanaka Precious Metals Co. Ltd., particle diameter: 40 Angstroms) were separately mixed with 33 parts by weight aliquots of each particle to prepare a colloidal mixture.
• 1.0 parts by weight of silver powder (Tanaka Precious Metals Co. Ltd.), having a particle diameter ranging from 0.2-1.0 ⁇ m and an average particle diameter of 0.7 ⁇ m, were added to 99.25 parts by weight of this mixture.
• the blending ratio of each substance in the composition of the present example was 33.0025% by weight of alumina, 33.0025% by weight of silica, 33.0025% by weight of titanium oxide, 0.0025% by weight of platinum and 0.99% by weight of silver.
• a composition was formed in the same manner as Example 1 with the exception of changing the content of the composition to 49.499% by weight of alumina, 49.499% by weight of titanium oxide (titania), 0.002% by weight of platinum and 1.0% by weight of silver.
• the resulting composition was diluted with pure water until it had a fluidity that allowed it to be sprayed, after which it was sprayed and uniformly dispersed and then heated for 10 minutes to 1 hour at about 50-150° C. to produce a composition in the form of a fine particulate powder.
• Example 2 5% by weight of the composition obtained in Example 2 was mixed into polyester chips to produce a master batch. 10% by weight of this master batch was then mixed into polyester during fiber spinning to produce antithrombotic fibers (polyester). Thus, the proportion of antithrombotic composition in the polyester fibers was 0.5% by weight.
• the produced fibers were I: long fibers (filaments) of 75 denier and 72 filament and II: short fibers (staples) of 6 denier and 51 mm hollow fiber.
• Example 2 5% by weight of the composition obtained in Example 2 was mixed into polyethylene chips to produce a master batch. 10% by weight of this master batch was then mixed in during the production of polyethylene pipes. Thus, the proportion of antithrombotic composition in the pipes was 0.5% by weight. In addition, the resulting pipes had a diameter (outer diameter) of 5 mm and length of 7 mm.
• Fiber blending ratio 100% antithrombotic fibers (polyester)
• Form Double-sided raised fibers, 140 cm wide ⁇ 200 cm long
• Fiber blending ratio Raised fibers—50% antithrombotic fibers (polyester), 50% cotton
• Raised fibers two ply blended yarn of No.40 cotton used for the antithrombotic fibers (polyester)
• Body case 100% cotton
• Body cover 100% cotton
• Fiber blending ratio 97% antithrombotic fibers (polyester), 3% polyurethane fabric
• Fiber blending ratio 97% antithrombotic fibers (polyester), 3% polyurethane fabric
• Subjects 20 persons hospitalized for routine health examinations.
• Method The subjects were divided into a group I and a group II using the envelope method. The subjects were then allowed to nap for 2 hours starting at 2:00 PM using two types of bedding and sleepwear in the manner described below (refer to Table 1). While the subjects were asleep, the room temperature was kept at 24° C. and the subjects were prohibited from drinking starting 1 hour before napping.
• Day 1 Bedding and sleepwear of the present invention were used (antithrombotic sheets, blanket, mattress pad, pillow, shirt and trousers)
• Day 2 Ordinary bedding and sleepwear were used (sheets, blanket, mattress pad, pillow, shirt and trousers)
• Form Double-sided raised fibers, 140 cm wide ⁇ 200 cm long
• Body cover 100% cotton
• Fiber blending ratio 100% polyester fabric Study Period: Feb. 21, 2001 to Mar. 15, 2001
• Others ⁇ circle over (1) ⁇ A disorder derived from arterial scleosis (A) . . .
• vascular endothelial cells have potent anticoagulation function and a strong negative charge, they mutually repel platelets having a similar negative charge. Moreover, endothelial cells also inhibit platelet function by releasing NO (nitrogen oxide) and PGI2 (prostaglandin), and demonstrate potent antithrombotic function overall by producing and releasing TM (thrombomodulin) and t-PA (tissue plasminogen activator).
• NO nitrogen oxide
• PGI2 prostaglandin
• the amount of PGF increased by about 10% (variation range: 5 to 15%) in Group K AFTER, while the amount of PGF tended to decrease about 10% (variation range: ⁇ 7 to ⁇ 27%) in Group PL AFTER.
• Variations of PAI-1, P-selectin, TX-B2 and PLT can be indicators of activation of platelet function. Platelets are normally maintained in a dormant state, while in the state in which the function of vascular endothelial cells is dominant, platelets are mutually repelled due to the negative charge of glycoproteins on the surface of vascular endothelial cells, and so the adhesion and aggregation of platelets to vascular walls is being inhibited. The variations in PAI-1, P-selectin, TX-B2 and platelet levels are shown in FIG. 8.
• PAI-1 exhibited a decreasing tendency (variation range: ⁇ 7 to ⁇ 33%) of 21% on average in Group K AFTER, and exhibited an increasing tendency (variation range: ⁇ 9.8 to +8.2%) of 3.1% on average in Group PL AFTER.
• P-selectin exhibited an increasing tendency in Group A for Groups K and PL, and although it decreases ( ⁇ 23 to ⁇ 18.7%) in Groups B and C for Group K, it only decreases mildly in Groups B and C for Group PL ( ⁇ 3 to ⁇ 3.4%).
• TX-B2 increased prominently in Group C for Group K, but exhibited a definite decrease in Group PL-C. Namely, although PAI-I and P-selectin exhibited minute increases and decreases throughout Groups K and PL, when platelet function is considered overall after adding TX-B2, platelet function was observed to move in the direction of a thrombogenic tendency as a result of promotion of overall platelet function in Group K AFTER, while in Group PL AFTER, since a decreasing tendency was observed for TX-B2, a hemorrhagotropic tendency is thought to have been exhibited due to inhibition of platelet function.
• fibrinogen which is coagulation factor I, factor IV, Ca ++ , and the thrombin controlling factors of antithrombin and MDA-LDL.
• Electrolytes other than Ca (K, Na and Cl) exhibited variations that were nearly all within the physiologically normal range of no more than 1 mEq/L, and since variations in TT and HTP were also extremely small, a study in the form of table was omitted.
• MDA-LDL Although mild decreases were exhibited after napping for both Groups K and PL, in the case of variations to this degree, MDA-LDL was not considered to lower the antithrombotic action of endothelial cells by inhibiting the expression of TM and t-PA by endothelial cells and enhancing the expression of tissue factor PAI-1.
• noradrenaline levels were elevated to the vicinity of the upper limit in all BEFORE cases for both Groups K and PL, in the AFTER cases, noradrenaline levels had similarly decreased to the level of 45-55% on average for both Groups K and PL. Since the stimulatory action on sympathetic nerve receptors decreases due to the reduction by half in noradrenaline levels, decreased circulating blood volume due to a reduction in peripheral vascular resistance, and decreased BV and PV due to reduced blood flow rate were observed.
• PAI-1 is produced in vascular endothelial cells, vascular smooth muscle cells and fat cells, and is the main inhibitory factor of t-PA. PAI-1 is also present in platelets, and is released accompanying platelet aggregation. The PAI-1 derived from platelets is mainly released at the sites of thrombi, and irreversibly binds to fibrin to exist in a concentrated form around fibrin to neutralize the activity of t-PA.
• PAI-1 exhibited a decreasing tendency in Groups A, B and C of the control group (Group K), it exhibited a somewhat increasing tendency in Groups B and C of Group PL.
• Platelets have a positive feedback pathway that promotes activation of surrounding platelets, in which pathway they produce the potent platelet activating substance TX-A2 when platelets are activated.
• TX-A2 is an extremely unstable substance that has a half-life of about 20 seconds, after which it is broken down to TX-B2. Changes in the levels of TX-B2 indicate the activation state of platelet function.
• TX-B2 exhibited decreasing tendencies after napping in Groups A and B of Group K and in Groups A and B of Group PL. In contrast, despite exhibiting a prominent increasing tendency after napping in Group C of Group K, it exhibited a remarkable decreasing tendency in Group C AFTER of Group PL.
• TX-B2 in Group C of Group PL are thought to indicate action that resembles that of anti-inflammatory agents and analgesics such as aspirin and indometacin which inhibit the enzyme activities of enzymes such as cyclooxygenase and phosphorylase A2 that are involved in TX-A2 synthesis pathway.
• analgesics such as aspirin and indometacin which inhibit the enzyme activities of enzymes such as cyclooxygenase and phosphorylase A2 that are involved in TX-A2 synthesis pathway.
• Group K Fibrinogen level: Down 6.5% on average, 0.6 second delay
• Group PL Fibrinogen level: Down 6.6% on average, 0.6 second delay
• ATIII levels decreased by 7.8% on average in Group K and by 6.4% on average in Group PL. Since ATIII is normally present in considerable excess with respect to the amount of thrombin formed, these degrees of decreases can be adequately dealt with in terms of the amount of thrombin formed. Consequently, the formed thrombin is bound by fibrinogen, TM (thrombomodulin) and ATTIII, and its activity is controlled. Namely, the thrombin control function is judged to be functioning well. On the basis of this finding, in consideration of variations in LDL, t-PA, TM and ATIII overall, the antithrombotic properties of vascular endothelial cells are thought to be maintained between in Group PL than in Group K.
• the promotion of antithrombotic action caused by a decrease in TX-B2 is thought to be quite significant due to the production of TX-B2 being strongly inhibited in Group C AFTER of Group PL as shown in Table 8, and the thrombotic tendency caused by decreased PDF resulting from the mild decrease in PGF production.
• the tendencies associated with the antithrombotic action of the composition of the present invention observed following napping were determined to constitute action dominated by antithrombotic properties without a hemorrhagic tendency becoming dominant in the same manner as that which occurs when using a small amount of aspirin.
• the antithrombotic composition of the present invention is a kind of ceramics which absorbs and resonates the minute amounts of vegetative light rays released from the body (equivalent to 5-15 microns) and amplifies them 1.2-1.5 times to radiate new vegetative light rays. Namely, together with exhibiting fat infrared effects, since the penetrating ability of the radiated energy is proportional to the square root of the wavelength, and penetrating ability increases the longer the wavelength, the composition of the present invention enhances the energy penetrating effect and negative ion (OH ⁇ ) effect due to the action of amplifying and radiating absorbed energy and the action of molecular translation.
• filters consisting of 100% fibers (polyester) containing the composition (Example 2) of the present invention and 100% ordinary polyester fibers (normal filter) were produced for use as samples, a mixed gas of oxygen and nitrogen was passed through the filters, xylene was burned and the minimum oxygen concentrations at those times were measured.
• fibers containing the antithrombotic composition of the present invention also passed the strict antimicrobial effect tests defined by the FDA (United States Food and Drug Administration) and AATCC (American Association of Textile Chemists and Colorists) (refer to Table 12).
• antimicrobial effect tests were conducted by inoculating Petri dishes with Staphylococcus aureus and Klebsiella pneumoniae and measuring the number of bacteria immediately after and 24 hours after inoculation with antithrombotic fibers of the present invention and polyester fibers (control).
• TABLE 12 Anti bacterial test test method FDA U.S. Pharmacopoeia 23 Microbial Limit Test (61) Test Results Limit General viable cell count (CFU/g) 1.0 ⁇ 10 — E.
• fibers containing the composition of the present invention are also worthy of attention as fibers capable of preventing nosocomial infections and domestic infections.
• composition of the present invention as well as bedding, sleepwear and other articles containing the same are capable of allowing antithrombotic properties to be dominant without allowing the occurrence of a hemorrhagic tendency.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Epidemiology (AREA)
• Inorganic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Manufacturing & Machinery (AREA)
• Textile Engineering (AREA)
• Polymers & Plastics (AREA)
• Materials Engineering (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Diabetes (AREA)
• Hematology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Materials For Medical Uses (AREA)
• Compositions Of Oxide Ceramics (AREA)
• Chemical Or Physical Treatment Of Fibers (AREA)
• Artificial Filaments (AREA)
• Bedding Items (AREA)
• Undergarments, Swaddling Clothes, Handkerchiefs Or Underwear Materials (AREA)

Priority Applications (1)

Applications Claiming Priority (3)

Related Child Applications (1)

Publications (1)

Family

ID=29727548

Family Applications (2)

Family Applications After (1)

Country Status (12)

Cited By (5)

Families Citing this family (6)

Citations (3)

Family Cites Families (16)

• 2003
  • 2003-06-05 AT AT03730822T patent/ATE526976T1/de not_active IP Right Cessation
  • 2003-06-05 JP JP2004510809A patent/JP4712378B2/ja not_active Expired - Lifetime
  • 2003-06-05 BR BR0305015-7A patent/BR0305015A/pt not_active IP Right Cessation
  • 2003-06-05 TW TW092115287A patent/TW200402402A/zh unknown
  • 2003-06-05 WO PCT/JP2003/007110 patent/WO2003103690A1/ja active Application Filing
  • 2003-06-05 CN CNB038009544A patent/CN100391470C/zh not_active Expired - Lifetime
  • 2003-06-05 AU AU2003242081A patent/AU2003242081B2/en not_active Ceased
  • 2003-06-05 EP EP03730822A patent/EP1510216B8/en not_active Expired - Lifetime
  • 2003-06-05 CA CA002461444A patent/CA2461444A1/en not_active Abandoned
  • 2003-06-05 US US10/492,341 patent/US20040202899A1/en not_active Abandoned
  • 2003-06-05 KR KR1020047009292A patent/KR100621452B1/ko active IP Right Grant
• 2004
  • 2004-01-30 NO NO20040416A patent/NO20040416L/no not_active Application Discontinuation
• 2006
  • 2006-08-10 US US11/502,081 patent/US8104482B2/en active Active
• 2008
  • 2008-02-08 JP JP2008029181A patent/JP2008239606A/ja active Pending

Patent Citations (3)

Also Published As

Similar Documents

Legal Events